TB Clip October 2023 (2) article image

편집자 한마디!

국내외 결핵(TB)뉴스

학술연구자료

STOP-TB 한국사무국 소식

TB Clip October 2023 (2) article image

WHO Global TB Program은 WHO Academy와 협력하여 일상적인 의료 시설 데이터를 활용하는 온라인 과정인 Tuberculosis를 런칭하였습니다. 일상적인 TB surveillance data를 분석, 해석, 제시하는 방법과 결과를 활용하는 방법을 배우며, 결핵 데이터의 기록 및 보고에 관여하는 관계자분들을 위한 강좌라고 합니다. 이 과정은 무료이나, WHO Academy에 등록이 필요하다고 합니다. 아쉽게도 한국어 제공은 안되나, 관심있으신 분들의 수강 부탁드립니다.

The World Health Organization (WHO) will host a webinar on 3 November 2023 to launch an operational handbook and an e-course on TB and mental health conditions. Register for the event here.

The World Health Organization (WHO) Global TB Program in collaboration with the WHO Academy announced the launch of the e-course, Harnessing the power of routine health facility data: Tuberculosis. The e-course can be accessed on the WHO Academy platform here. The course is free of charge and can be followed at one's own pace (approximately 5 hours of learning).

In preparation for the Union World Conference on Lung Health to be held in Paris, France on 15-18 November 2023, the TB Vaccine Advocacy Roadmap (TB Vax ARM) will host a virtual meeting on 2 November 2023 exploring what's next for TB research and development (R&D) following the United Nations High-Level Meeting on TB (HLM). Register for the meeting here.

The International Union Against Tuberculosis and Lung Disease (The Union) launched a new free online course on child TB diagnosis: Interpretation of chest X-rays (CXRs) in children with presumptive TB in high burden settings. Full details about the course are available here.

The World Health Organization announced the release of ScreenTB (screentb.org) - a web-based tool designed to assist countries in prioritizing risk groups for TB screening, as well as in developing screening and prevention approaches tailored to country contexts. ScreenTB is available free of charge for all.

The World Health Organization (WHO) Global TB Program is providing secretariat support to the TB vaccine accelerator council, which was recently established to facilitate the development, licensing and use of safe TB vaccines that are impactful in halting the TB epidemic. Civil society representatives with relevant expertise and experience are invited to respond to a call for expression of interest to be engaged in the leadership group of the Council. The deadline to apply is 18 October 2023. For full details about the call, click here.

Siemens Healthineers and the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) announced a partnership to accelerate the use of artificial intelligence (AI) in X-ray screening for TB. The two organizations will work together to speed up the adoption of AI in chest X-rays to improve efficiency and accuracy. Source: Global Fund

Johnson & Johnson recently announced that it would lift patents on bedaquiline, a key component in the treatment of multidrug-resistant TB (MDR-TB). This is an important move towards equitable access to TB treatment, but it is unclear how soon the changes will filter down to national programs in high burden countries like South Africa. Source: Health-e News

The report portrays how GSK's financial interests have – and will likely continue to – set back progress against the world's deadliest infectious disease lays bare just how egregiously large pharmaceutical companies bilk the global public, and makes an urgent case for government and philanthropic funders to take action and demand better.

Treatment Action Group (TAG) released the first TB chapter of its 2023 Pipeline Report offering a contextualized overview of TB vaccine candidates currently in clinical development. Tuberculosis Vaccines by Mike Frick is now available online as a downloadable PDF.

Smoking was associated with a significantly increased risk of recurrence and mortality during treatment among patients with TB, according to study findings published, in Chest.

A new study published in the Journal of Experimental Medicine described a previously unappreciated role for a class of immune cells in the early stages of TB infection.

Researchers have studied why TB bacteria form long strands and how this affects their infectivity. Their findings could lead to new therapies and have been published, in Cell.

A recent Npj Vaccines study, discussed the success and challenges of developing different TB vaccine types.

Vulnerable populations face a substantially higher burden of TB than general populations face, according to systematic review findings published in The Lancet Infectious Diseases. Asylum seekers, refugees, those with HIV, incarcerated individuals, and homeless individuals often had TB prevalence ratios greater than 25 vs the general population.

A study, published in The Lancet Microbe, has found that antibiotics used to treat TB kill other potentially useful bacteria. The 'killing effect' was more pronounced in the first two weeks of the patient taking antibiotics, after which the bacteria began to recover, achieving a similar level of abundancy as before treatment within 2 months.

Adding dexamethasone to treatment for TB meningitis among heavily immunosuppressed HIV-positive patients in a low-resource setting did not significantly improve survival or confer any other measured benefits, a randomized controlled trial, published in the the New England Journal of Medicine, showed.

A study, published in Nature Microbiology, showed that, when given intravenously, the only commercially available vaccine against TB (Bacillus Calmette-Guérin vaccine) successfully and safely prevents lung infection in monkeys, or primates, infected with the simian form of HIV, called SIV. This is despite the vaccine being contraindicated for people living with HIV.

An article in 2023 issue of TAGline takes stock of the state of TB preventive treatment (TPT) around the world, exploring nuances that help explain why newly validated TPT regimens are still not universally used by household contacts of people living with active TB disease.

RESIST-TB released its October 2023 newsletter with the latest updates and research publications on drug-resistant TB.